Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seitz, R. J.
Right arrow Articles by Siebler, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seitz, R. J.
Right arrow Articles by Siebler, M.
Related Collections
Right arrow All Clinical trials
Right arrow All Cerebrovascular disease/Stroke
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrow Infarction
NEUROLOGY 2004;62:2110-2112
© 2004 American Academy of Neurology
Brief Communications

The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions

R. J. Seitz, MD, S. Meisel, MD, M. Moll, MD, H. -J. Wittsack, PhD, U. Junghans, MD and M. Siebler, MD

From the Department of Neurology (Drs. Seitz, Meisel, Moll, Junghans, and Siebler), Institute of Diagnostic Radiology (Dr. Wittsack), Heinrich-Heine University of Düsseldorf, Germany.

Address correspondence and reprint requests to Dr. Rüdiger J. Seitz, Department of Neurology, University Hospital Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany; e-mail: seitz{at}neurologie.uni-duesseldorf.de

To determine the effect of systemic thrombolysis with low-dose recombinant tissue plasminogen activator (rtPA) and the body-weight adjusted platelet GPIIb/IIIa receptor antagonist tirofiban, the authors performed lesion volumetry on magnetic resonance perfusion and diffusion images recorded before thrombolysis and on T2-weighted magnetic resonance images on day 8. Treatment with rtPA and tirofiban (n = 13) resulted in a 50% lesion reduction (p < 0.03), while lesion reduction was less in rtPA treatment (n = 16) and absent in nontreated patients (n = 18).

Received July 28, 2003. Accepted in final form January 29, 2004.




This article has been cited by other articles:


Home page
 Am. J. Neuroradiol.Home page
P.G. Kranz and J.D. Eastwood
Does Diffusion-Weighted Imaging Represent the Ischemic Core? An Evidence-Based Systematic Review
AJNR Am. J. Neuroradiol., June 1, 2009; 30(6): 1206 - 1212.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Stoll, C. Kleinschnitz, and B. Nieswandt
Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment
Blood, November 1, 2008; 112(9): 3555 - 3562.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
R. J. Seitz, S. Meisel, P. Weller, U. Junghans, H.-J. Wittsack, and M. Siebler
Initial Ischemic Event: Perfusion-weighted MR Imaging and Apparent Diffusion Coefficient for Stroke Evolution
Radiology, December 1, 2005; 237(3): 1020 - 1028.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
C. A. Molina and J. L. Saver
Extending Reperfusion Therapy for Acute Ischemic Stroke: Emerging Pharmacological, Mechanical, and Imaging Strategies
Stroke, October 1, 2005; 36(10): 2311 - 2320.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.